Archimedes Pharma opens US headquarters
BEIP grant sways firm to locate in New Jersey
Archimedes Pharma, a UK-based pharmaceutical company focused on the oncology, pain, neurology and critical care sectors, is setting up a US operation in Bedminster, New Jersey as it prepares to launch its first US product.
Archimedes' lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain, received a Positive Opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) in June. A New Drug Application (NDA) for the drug was submitted to the US Food and Drug Administration (FDA) in August 2009 and discussions are ongoing.
The company said up to 75 people would be hired in the US, ranging from sales and marketing, regulatory and finance positions to human resources and medical affairs.
The New Jersey Economic Development Authority awarded a Business Employment Incentive Programme (BEIP) grant to Archimedes Pharma US to create these positions.
Jeffrey Buchalter, chief executive of Archimedes Pharma, says the opening of the Bedminster headquarters is a ‘significant milestone’ in Archimedes' development.
‘We are in the process of establishing our own US organisation and are actively recruiting top-tier senior-level management positions to support market penetration across the US and globally,’ he said. He added that the BEIP grant was the main reason why Archimedes chose to locate its new offices in New Jersey.
